September 22, 2015 7:03am

Mr. Schlossberg and Mr. Lapointe will serve as independent members of the Board of Directors; the appointments regain compliance with the listing standards of the NYSE MKT regarding the majority of independent directors' requirement as well as having three independent directors serving on the Audit Committee.


 

Mr. Schlossberg has more than 15 years of experience in the biotechnology, pharmaceutical and medical device industries, and broad expertise in general management, legal affairs, finance, business development, and mergers and acquisitions.  Mr. Schlossberg has been appointed to the Audit and Nominating & Governance Committees of the Board.

Mr. Schlossberg currently serves as Senior Vice President, General Counsel and Corporate Secretary of Impax Laboratories, Inc., where he is part of the senior management team responsible for the strategic direction and financial condition of the company. He leads the legal team and previously had responsibility for the healthcare compliance team.  Prior to Impax, he served as Vice President, Associate General Counsel of Amgen Inc., where he led the legal department, and was responsible for corporate governance, securities law, licensing, mergers and acquisitions, global operations, and sales and marketing compliance. Prior to joining Amgen, he held legal and business positions at Medtronic, Inc., and legal positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie Alexander & Ferdon. Mr. Schlossberg holds a Bachelor of Sciences in business administration, finance from the University of Southern California and a Juris Doctor degree from Emory University.

 

Mr. Lapointe has deep and broad executive, financial, operational, commercial and general management experience in large and small biopharmaceutical companies. Mr. Lapointe has been appointed to the Compensation Committee of the Board.

Mr. Lapointe is currently the Chief Executive Officer of Cerium Pharmaceuticals, Inc., a specialty pharmaceutical company. He previously served as Chief Operating Officer and then as Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc., a pharmaceutical company focused on rare disorders and the U.S. wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A. Lapointe is a Certified Public Accountant (Illinois). He holds a Bachelor of Commerce degree from Concordia University of Montreal, a Graduate Diploma in Public Accountancy from McGill University of Montreal and a Master of Business Administration degree from Duke University. Mr. Lapointe also serves on the Boards of Directors of SciClone Pharmaceuticals, Inc., Soligenix, Inc., and Raptor Pharmaceuticals Corp.